Blood test for immune markers in skin cancer patients on cemiplimab
Treatments studied
Part of Cancer, Immune system & allergy, Skin clinical trials.
This trial is testing whether a new blood test can predict how well the drug cemiplimab works for skin cancer and if it causes side effects. It may help doctors better match treatments to patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- Your blood counts and liver/kidney function are within certain safe ranges (your doctor can check)
- You do not have a serious active infection like HIV, hepatitis B, or hepatitis C
- You have not had a strong immune-suppressing treatment for an autoimmune disease recently
- You do not have untreated or growing brain metastases
- You are willing to use effective contraception if you or your partner could become pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug (cemiplimab) injected directly into early-stage skin cancer (squamous cell carcinoma) to see if it can shrink or cure the cancer before surgery. It may help patients avoid more extensive surgery or reduce the chance of the cancer coming back.
This trial looks at whether a simple blood test (D-dimer) taken before starting the drug cemiplimab can help predict how well the treatment works for advanced skin cancer. It aims to find out if this test can guide better care for patients with this condition.
This trial tests whether the immunotherapy drug cemiplimab can treat advanced squamous cell skin cancer in people who have had a kidney transplant. It aims to see if the drug can shrink tumors while keeping the transplanted kidney working well.
This Phase 1 trial tests the drug cemiplimab given before and after surgery to reduce the chance that high-risk cutaneous squamous cell cancer comes back. You may be a candidate if your cancer is high-risk on pathology or imaging and is planned for surgical removal.
This early-phase study tests cemiplimab (an immune therapy that helps your immune system attack cancer) given before surgery. It aims to shrink tumors and improve outcomes for people with Merkel cell cancer or certain locally advanced skin squamous cell cancers (CSCC).
This trial tests cemiplimab, an immunotherapy drug, as a first treatment for advanced basal cell carcinoma that cannot be removed with surgery or radiation. The goal is to see if it can shrink or control the cancer.
Hear when a new Cutaneous Squamous Cell Carcinoma (CSCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.